Repare Therapeutics Inc. (RPTX) Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Repare Therapeutics Inc. (“Repare” or “the Company”) (NASDAQ: RPTX). Investors who purchased Repare securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/RPTX.

Investigation Details:

On February 12, 2024, Repare issued a press release “announc[ing] . . . that it will regain global development and commercialization rights to camonsertib (RP-3500), a potential best-in-class oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase), following termination of its collaboration agreement with Roche.” The press release stated that “Roche notified Repare that, effective May 7, 2024, it is terminating its worldwide license and collaboration agreement for the development and commercialization of camonsertib following a review of Roche’s pipeline and evolving external factors.” On this news, Repare’s stock price fell $1.31 per share, or 15.58%, to close at $7.10 per share on February 13, 2024.

What’s Next?

If you are aware of any facts relating to this investigation or purchased Repare securities, you can assist this investigation by visiting the firm’s site: bgandg.com/RPTX. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman:

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240315655552/en/

The Repare Therapeutics Stock at the time of publication of the news with a raise of +2,11 % to 5,33USD on Nasdaq stock exchange (15. März 2024, 15:06 Uhr).